NLRP3 inflammasome and MS/EAE

Autoimmune Diseases

Volumn 2013, Issue , 2013, Pages

  Inoue, Makoto ^a   Shinohara, Mari L ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYOPYRIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME;

ALLERGIC ENCEPHALOMYELITIS; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CHEMOTAXIS; DISEASE COURSE; GENE LOCUS; HUMAN; IMMUNOCOMPETENT CELL; MUCKLE WELLS SYNDROME; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 84873343026     PISSN: None     EISSN: 20900430     Source Type: Journal    
DOI: 10.1155/2013/859145     Document Type: Review

References (85)

1. Schroder K., Tschopp J., The inflammasomes. Cell 2010 140 6 821 832 2-s2.0-77950362382 10.1016/j.cell.2010.01.040
2. Brodsky I. E., Monack D., NLR-mediated control of inflammasome assembly in the host response against bacterial pathogens. Seminars in Immunology 2009 21 4 199 207 2-s2.0-69949088960 10.1016/j.smim.2009.05.007
3. Tschopp J., Schroder K., NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nature Reviews Immunology 2010 10 3 210 215 2-s2.0-77649179433 10.1038/nri2725
4. Cookson B. T., Brennan M. A., Pro-inflammatory programmed cell death. Trends in Microbiology 2001 9 3 113 114 2-s2.0-0035283318
5. Fink S. L., Cookson B. T., Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infection and Immunity 2005 73 4 1907 1916 2-s2.0-16244362671 10.1128/IAI.73.4.1907-1916.2005 (Pubitemid 40470787)
6. Agostini L., Martinon F., Burns K., McDermott M. F., Hawkins P. N., Tschopp J., NALP3 forms an IL-1 β -processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004 20 3 319 325 2-s2.0-1642285783 10.1016/S1074-7613(04)00046-9 (Pubitemid 38388233)
7. Allen I. C., Scull M. A., Moore C. B., Holl E. K., McElvania-TeKippe E., Taxman D. J., Guthrie E. H., Pickles R. J., Ting J. P. Y., The NLRP3 inflammasome mediates in vivo innate immunity to influenza a virus through recognition of viral RNA. Immunity 2009 30 4 556 565 2-s2.0-64049111768 10.1016/j.immuni.2009.02.005
8. Mariathasan S., Weiss D. S., Newton K., McBride J., O'Rourke K., Roose-Girma M., Lee W. P., Weinrauch Y., Monack D. M., Dixit V. M., Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006 440 7081 228 232 2-s2.0-32944470765 10.1038/nature04515 (Pubitemid 43372102)
9. Gross O., Poeck H., Bscheider M., Dostert C., Hannesschläger N., Endres S., Hartmann G., Tardivel A., Schweighoffer E., Tybulewicz V., Mocsai A., Tschopp J., Ruland J., Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009 459 7245 433 436 2-s2.0-67349271142 10.1038/nature07965
10. Martinon F., Pétrilli V., Mayor A., Tardivel A., Tschopp J., Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006 440 7081 237 241 2-s2.0-32944468985 10.1038/nature04516 (Pubitemid 43372104)
11. Halle A., Hornung V., Petzold G. C., Stewart C. R., Monks B. G., Reinheckel T., Fitzgerald K. A., Latz E., Moore K. J., Golenbock D. T., The NALP3 inflammasome is involved in the innate immune response to amyloid- β Nature Immunology 2008 9 8 857 865 2-s2.0-47849085872 10.1038/ni.1636
12. Dostert C., Pétrilli V., van Bruggen R., Steele C., Mossman B. T., Tschopp J., Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008 320 5876 674 677 2-s2.0-43249125839 10.1126/science.1156995 (Pubitemid 351928351)
13. Hornung V., Bauernfeind F., Halle A., Samstad E. O., Kono H., Rock K. L., Fitzgerald K. A., Latz E., Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunology 2008 9 8 847 856 2-s2.0-47849097202 10.1038/ni.1631
14. Perregaux D., Gabel C. A., Interleukin-1 β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. Journal of Biological Chemistry 1994 269 21 15195 15203 2-s2.0-0028175838
15. Pétrilli V., Papin S., Dostert C., Mayor A., Martinon F., Tschopp J., Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death and Differentiation 2007 14 9 1583 1589 2-s2.0-34548027736 10.1038/sj.cdd.4402195 (Pubitemid 47278844)
16. Kanneganti T. D., Lamkanfi M., Kim Y. G., Chen G., Park J. H., Franchi L., Vandenabeele P., Núñez G., Pannexin-1-mediated recognition of bacterial molecules activates the cryopyrin inflammasome independent of toll-like receptor signaling. Immunity 2007 26 4 433 443 2-s2.0-34247118826 10.1016/j.immuni.2007.03.008 (Pubitemid 46603000)
17. Zhou R., Yazdi A. S., Menu P., Tschopp J., A role for mitochondria in NLRP3 inflammasome activation. Nature 2011 469 221 225
18. Nakahira K., Haspel J. A., Rathinam V. A. K., Lee S. J., Dolinay T., Lam H. C., Englert J. A., Rabinovitch M., Cernadas M., Kim H. P., Fitzgerald K. A., Ryter S. W., Choi A. M. K., Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nature Immunology 2011 12 3 222 230 2-s2.0-79951642032 10.1038/ni.1980
19. Martinon F., Signaling by ROS drives inflammasome activation. European Journal of Immunology 2010 40 3 616 619 2-s2.0-77749304032 10.1002/eji.200940168
20. Hoffman H. M., Mueller J. L., Broide D. H., Wanderer A. A., Kolodner R. D., Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nature Genetics 2001 29 3 301 305 2-s2.0-0035179970 10.1038/ng756 (Pubitemid 33096455)
21. Feldmann J., Prieur A. M., Quartier P., Berquin P., Certain S., Cortis E., Teillac-Harnel D., Fischer A., De Saint Basile G., Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. American Journal of Human Genetics 2002 71 1 198 203 2-s2.0-0036302235 10.1086/341357 (Pubitemid 34734724)
22. Ting J. P. Y., Kastner D. L., Hoffman H. M., CATERPILLERs, pyrin and hereditary immunological disorders. Nature Reviews Immunology 2006 6 3 183 195 2-s2.0-33344476398 10.1038/nri1788 (Pubitemid 43290988)
23. Strowig T., Henao-Mejia J., Elinav E., Flavell R., Inflammasomes in health and disease. Nature 2012 481 278 286 10.1038/nature10759
24. Conforti-Andreoni C., Ricciardi-Castagnoli P., Mortellaro A., The inflammasomes in health and disease: from genetics to molecular mechanisms of autoinflammation and beyond. Cellular and Molecular Immunology 2011 8 2 135 145 2-s2.0-79952393266 10.1038/cmi.2010.81
25. de Nardo D., Latz E., NLRP3 inflammasomes link inflammation and metabolic disease. Trends in Immunology 2011 32 8 373 379 2-s2.0-79960920271 10.1016/j.it.2011.05.004
26. Menu P., Vince J. E., The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clinical and Experimental Immunology 2011 166 1 1 15 2-s2.0-79960339571 10.1111/j.1365-2249.2011.04440.x
27. Compeyrot-Lacassagne S., Tran T. A., Guillaume-Czitrom S., Marie I., Koné-Paut I., Brain multiple sclerosis-like lesions in a patient with Muckle-Wells syndrome. Rheumatology 2009 48 12 1618 1619 2-s2.0-75649137216 10.1093/rheumatology/kep321
28. Dodé C., le Dû N., Cuisset L., Letourneur F., Berthelot J. M., Vaudour G., Meyrier A., Watts R. A., Scott D. G. I., Nicholls A., Granel B., Frances C., Garcier F., Edery P., Boulinguez S., Domergues J. P., Delpech M., Grateau G., New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes. American Journal of Human Genetics 2002 70 6 1498 1506 2-s2.0-18344385660 10.1086/340786 (Pubitemid 34533897)
29. Furlan R., Filippi M., Bergami A., Rocca M. A., Martinelli V., Poliani P. L., Grimaldi L. M. E., Desina G., Comi G., Martino G., Peripheral levels of caspase-1 mRNA correlate with disease activity in patients with multiple sclerosis; a preliminary study. Journal of Neurology Neurosurgery and Psychiatry 1999 67 6 785 788 2-s2.0-0032702860
30. Ming X., Li W., Maeda Y., Blumberg B., Raval S., Cook S. D., Dowling P. C., Caspase-1 expression in multiple sclerosis plaques and cultured glial cells. Journal of the Neurological Sciences 2002 197 1-2 9 18 2-s2.0-0037094037 10.1016/S0022-510X(02)00030-8 (Pubitemid 34462139)
31. Huang W. X., Huang P., Hillert J., Increased expression of capase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis. Multiple Sclerosis 2004 10 5 482 487 2-s2.0-4444254434 10.1191/1352458504ms1071oa (Pubitemid 39207218)
32. NCBI-dbSNP Website
33. de Jong B. A., Huizinga T. W. J., Bollen E. L. E. M., Uitdehaag B. M. J., Bosma G. P. T., van Buchem M. A., Remarque E. J., Burgmans A. C. S., Kalkers N. F., Polman C. H., Westendorp R. G. J., Production of IL-1 β and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. Journal of Neuroimmunology 2002 126 1-2 172 179 2-s2.0-0035999548 10.1016/S0165-5728(02)00056-5 (Pubitemid 34521742)
34. Crusius J. B. A., Pena A. S., van Oosten B. W., Bioque G., Garcia A., Dijkstra C. D., Polman C. H., Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis. Lancet 1995 346 8980 979 980 2-s2.0-0029145466
35. Voltz R., Hartmann M., Spuler S., Scheller A., Mai N., Hohlfeld R., Yousry T., Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist. Journal of Neurology Neurosurgery and Psychiatry 1997 62 2 200 201 2-s2.0-0031053877 (Pubitemid 27090948)
36. de la Concha E. G., Arroyo R., Crusius J. B. A., Campillo J. A., Martin C., Varela De Seijas E., Peña A. S., Clavería L. E., Fernandez-Arquero M., Combined effect of HLA-DRB11501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. Journal of Neuroimmunology 1997 80 1-2 172 178 2-s2.0-0031454972 10.1016/S0165-5728(97)00153-7 (Pubitemid 28015338)
37. Feakes R., Sawcer S., Broadley S., Coraddu F., Roxburgh R., Gray J., Clayton D., Compston A., Interleukin 1 receptor antagonist (IL-1ra) in multiple sclerosis. Journal of Neuroimmunology 2000 105 1 96 101 2-s2.0-0034212944 10.1016/S0165-5728(00)00203-4 (Pubitemid 30125434)
38. Kantarci O. H., Atkinson E. J., Hebrink D. D., McMurray C. T., Weinshenker B. G., Association of two variants in IL-1 β and IL-1 receptor antagonist genes with multiple sclerosis. Journal of Neuroimmunology 2000 106 1-2 220 227 2-s2.0-0034237667 10.1016/S0165-5728(00)00202-2 (Pubitemid 30256096)
39. Luomala M., Lehtimäki T., Elovaara I., Wang X. Y., Ukkonen M., Mattila K., Laippala P., Koivula T., Hurme M., A study of interleukin-1 cluster genes in susceptibility to and severity of multiple sclerosis. Journal of the Neurological Sciences 2001 185 2 123 127 2-s2.0-0035310922 10.1016/S0022- 510X(01)00482-8 (Pubitemid 32318517)
40. Niino M., Kikuchi S., Fukazawa T., Yabe I., Sasaki H., Tashiro K., Genetic polymorphisms of IL-1 β and IL-1 receptor antagonist in association with multiple sclerosis in Japanese patients. Journal of Neuroimmunology 2001 118 2 295 299 2-s2.0-0035975266 10.1016/S0165-5728(01)00339-3 (Pubitemid 32728363)
41. Burger D., Molnarfi N., Weber M. S., Brandt K. J., Benkhoucha M., Gruaz L., Chofflon M., Zamvil S. S., Lalive P. H., Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1 β in human monocytes and multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America 2009 106 11 4355 4359 2-s2.0-63149114677 10.1073/pnas.0812183106
42. Nicoletti F., Patti F., di Marco R., Zaccone P., Nicoletti A., Meroni P., Reggio A., Circulating serum levels of IL-1ra in patients with relapsing remitting multiple sclerosis are normal during remission phases but significantly increased either during exacerbations or in response to IFN- β treatment. Cytokine 1996 8 5 395 400 2-s2.0-0030015204 10.1006/cyto.1996.0054
43. Yiangou Y., Facer P., Durrenberger P., Chessell I. P., Naylor A., Bountra C., Banati R. R., Anand P., COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurology 2006 6, article 12 2-s2.0-33645224970 10.1186/1471-2377-6-12
44. Matute C., Interaction between glutamate signalling and immune attack in damaging oligodendrocytes. Neuron Glia Biology 2007 3 4 281 285 2-s2.0-46749128950 10.1017/S1740925X08000033 (Pubitemid 351944151)
45. Caragnano M., Tortorella P., Bergami A., Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosis. Journal of Neuroimmunology 2012 245 93 97 10.1016/j.jneuroim.2012.02.002
46. Oyanguren-Desez O., Rodriguez-Antiguedad A., Villoslada P., Domercq M., Alberdi E., Matute C., Gain-of-function of P2X7 receptor gene variants in multiple sclerosis. Cell Calcium 2011 50 468 472 10.1016/j.ceca.2011.08.002
47. Amorini A. M., Petzold A., Tavazzi B., Eikelenboom J., Keir G., Belli A., Giovannoni G., Di Pietro V., Polman C., D'Urso S., Vagnozzi R., Uitdehaag B., Lazzarino G., Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clinical Biochemistry 2009 42 10-11 1001 1006 2-s2.0-67349252457 10.1016/j.clinbiochem.2009.03.020
48. Liu B., Shen Y., Xiao K., Tang Y., Cen L., Wei J., Serum uric acid levels in patients with multiple sclerosis: a meta-analysis. Neurological Research 2012 34 2 163 171 10.1179/1743132811Y.0000000074
49. Bever C. T. Jr., Garver D. W., Increased cathepsin B activity in multiple sclerosis brain. Journal of the Neurological Sciences 1995 131 1 71 73 2-s2.0-0029004145 10.1016/0022-510X(95)00039-5
50. Inoue M., Williams K. L., Oliver T., Vandenabeele P., Rajan J. V., Miao E. A., Shinohara M. L., Interferon- β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome. Science Signaling 2012 5 225 ra38 10.1126/scisignal.2002767
51. Gris D., Ye Z., Iocca H. A., Wen H., Craven R. R., Gris P., Huang M., Schneider M., Miller S. D., Ting J. P. Y., NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. Journal of Immunology 2010 185 2 974 981 2-s2.0-77955475968 10.4049/jimmunol.0904145
52. Inoue M., Williams K. L., Gunn M. D., Shinohara M. L., NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 2012 109 26 10480 10485 10.1073/pnas.1201836109
53. Jha S., Srivastava S. Y., Brickey W. J., Iocca H., Toews A., Morrison J. P., Chen V. S., Gris D., Matsushima G. K., Ting J. P. Y., The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. Journal of Neuroscience 2010 30 47 15811 15820 2-s2.0-78649396261 10.1523/JNEUROSCI.4088-10.2010
54. Furlan R., Martino G., Galbiati F., Poliani P. L., Smiroldo S., Bergami A., Desina G., Comi G., Flavell R., Su M. S., Adorini L., Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. Journal of Immunology 1999 163 5 2403 2409 2-s2.0-0033198269 (Pubitemid 29399158)
55. Ahmed Z., Doward A. I., Pryce G., Taylor D. L., Pocock J. M., Leonard J. P., Baker D., Cuzner M. L., A role for caspase-1 and -3 in the pathology of experimental allergic encephalomyelitis: inflammation versus degeneration. American Journal of Pathology 2002 161 5 1577 1586 2-s2.0-0036840008 (Pubitemid 35265518)
56. Sutton C., Brereton C., Keogh B., Mills K. H. G., Lavelle E. C., A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. Journal of Experimental Medicine 2006 203 7 1685 1691 2-s2.0-33745873727 10.1084/jem.20060285 (Pubitemid 44036274)
57. Badovinac V., Mostarica-Stojković M., Dinarello C. A., Stošić-Grujičić S., Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. Journal of Neuroimmunology 1998 85 1 87 95 2-s2.0-0032077870 10.1016/S0165-5728(98) 00020-4 (Pubitemid 28255441)
58. Shi F. D., Takeda K., Akira S., Sarvetnick N., Ljunggren H. G., IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN- γ by NK cells. Journal of Immunology 2000 165 6 3099 3104 2-s2.0-0034665289
59. Matute C., Torre I., Pérez-Cerdá F., Pérez- Samartín A., Alberdi E., Etxebarria E., Arranz A. M., Ravid R., Rodríguez-Antigüedad A., Sánchez-Gómez M. V., Domercq M., P2X7 receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. Journal of Neuroscience 2007 27 35 9525 9533 2-s2.0-34548398189 10.1523/JNEUROSCI.0579-07.2007 (Pubitemid 47358223)
60. Alvarez J. I., Dodelet-Devillers A., Kebir H., Ifergan I., Fabre P. J., Terouz S., Sabbagh M., Wosik K., Bourbonnière L., Bernard M., van Horssen J., De Vries H. E., Charron F., Prat A., The hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence. Science 2011 334 6063 1727 1731 10.1126/science.1206936
61. Ferrari C. C., Depino A. M., Prada F., Muraro N., Campbell S., Podhajcer O., Perry V. H., Anthony D. C., Pitossi F. J., Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. American Journal of Pathology 2004 165 5 1827 1837 2-s2.0-7244251521 (Pubitemid 39435180)
62. Sutton C. E., Lalor S. J., Sweeney C. M., Brereton C. F., Lavelle E. C., Mills K. H. G., Interleukin-1 and IL-23 Induce Innate IL-17 Production from γ δ T Cells, Amplifying Th17 Responses and Autoimmunity. Immunity 2009 31 2 331 341 2-s2.0-68649088121 10.1016/j.immuni.2009.08.001
63. Jander S., Stoll G., Differential induction of interleukin-12, interleukin- 18, and interleukin-1 β converting enzyme mRNA in experimental autoimmune encephalomyelitis of the Lewis rat. Journal of Neuroimmunology 1998 91 1-2 93 99 2-s2.0-0032476702 10.1016/S0165-5728(98)00162-3 (Pubitemid 28545248)
64. Wildbaum G., Youssef S., Grabie N., Karin N., Neutralizing antibodies to IFN- γ -inducing factor prevent experimental autoimmune encephalomyelitis. Journal of Immunology 1998 161 11 6368 6374 2-s2.0-0032400918 (Pubitemid 28536013)
65. Gutcher I., Urich E., Wolter K., Prinz M., Becher B., Interleukin 18-independent engagement of interleukin 18 receptor- α is required for autoimmune inflammation. Nature Immunology 2006 7 9 946 953 2-s2.0-33747623280 10.1038/ni1377 (Pubitemid 44263908)
66. Lalor S. J., Dungan L. S., Sutton C. E., Basdeo S. A., Fletcher J. M., Mills K. H. G., Caspase-1-processed cytokines IL-1 β and IL-18 promote IL-17 production by γ δ and CD4 T cells that mediate autoimmunity. Journal of Immunology 2011 186 10 5738 5748 2-s2.0-79956187649 10.4049/jimmunol.1003597
67. Fife B. T., Huffnagle G. B., Kuziel W. A., Karpus W. J., CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 2000 192 6 899 905 2-s2.0-0033807680 10.1084/jem.192.6.899
68. Huang D. R., Wang J., Kivisakk P., Rollins B. J., Ransohoff R. M., Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 2001 193 6 713 725 2-s2.0-0035911254 10.1084/jem.193.6.713 (Pubitemid 32524465)
69. Sørensen T. L., Sellebjerg F., Distinct chemokine receptor and cytokine expression profile in secondary progressive MS. Neurology 2001 57 8 1371 1376 2-s2.0-18544404188 (Pubitemid 32995713)
70. Misu T., Onodera H., Fujihara K., Matsushima K., Yoshie O., Okita N., Takase S., Itoyama Y., Chemokine receptor expression on T cells in blood and cerebrospinal fluid at relapse and remission of multiple sclerosis: imbalance of Th1/Th2-associated chemokine signaling. Journal of Neuroimmunology 2001 114 1-2 207 212 2-s2.0-0035283409 10.1016/S0165-5728(00)00456-2 (Pubitemid 32184743)
71. McManus C., Berman J. W., Brett F. M., Staunton H., Farrell M., Brosnan C. F., MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. Journal of Neuroimmunology 1998 86 1 20 29 2-s2.0-0032100683 10.1016/S0165-5728(98)00002-2 (Pubitemid 28293946)
72. Nelissen I., Dubois B., Goris A., Ronsse I., Carton H., Opdenakker G., Gelatinase B, PECAM-1 and MCP-3 gene polymorphisms in Belgian multiple sclerosis. Journal of the Neurological Sciences 2002 200 1-2 43 48 2-s2.0-0037102715 10.1016/S0022-510X(02)00129-6 (Pubitemid 34792740)
73. Kim J. V., Jiang N., Tadokoro C. E., Liu L., Ransohoff R. M., Lafaille J. J., Dustin M. L., Two-photon laser scanning microscopy imaging of intact spinal cord and cerebral cortex reveals requirement for CXCR6 and neuroinflammation in immune cell infiltration of cortical injury sites. Journal of Immunological Methods 2010 352 1-2 89 100 2-s2.0-71749097979 10.1016/j.jim.2009.09.007
74. Fukumoto N., Shimaoka T., Fujimura H., Sakoda S., Tanaka M., Kita T., Yonehara S., Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis. Journal of Immunology 2004 173 3 1620 1627 2-s2.0-3242754112 (Pubitemid 38971592)
75. Uede T., Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases. Pathology International 2011 61 5 265 280 2-s2.0-79955029805 10.1111/j.1440-1827.2011.02649.x
76. Chabas D., Baranzini S. E., Mitchell D., Bernard C. C. A., Rittling S. R., Denhardt D. T., Sobel R. A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J. R., Steinman L., The influence of the proinflammatory cytokine, osteopontin, on autoimmue demyelinating desease. Science 2001 294 5547 1731 1735 2-s2.0-0035941106 10.1126/science.1062960 (Pubitemid 33104847)
77. Jansson M., Panoutsakopoulou V., Baker J., Klein L., Cantor H., Cutting edge: attenuated experimental autoimmune encephalomyelitis in ETA-1/osteopontin-deficient mice. Journal of Immunology 2002 168 5 2096 2099 2-s2.0-0036499086 (Pubitemid 34171807)
78. Shinohara M. L., Kim J. H., Garcia V. A., Cantor H., Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. Immunity 2008 29 1 68 78 2-s2.0-44449146212 10.1016/j.immuni.2008.05.008
79. Hur E. M., Youssef S., Haws M. E., Zhang S. Y., Sobel R. A., Steinman L., Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nature Immunology 2007 8 1 74 83 2-s2.0-33846998653 10.1038/ni1415 (Pubitemid 46242361)
80. Shinohara M. L., Jansson M., Hwang E. S., Werneck M. B. F., Glimcher L. H., Cantor H., T-bet-dependent expression of osteopontin contributes to T cell polarization. Proceedings of the National Academy of Sciences of the United States of America 2005 102 47 17101 17106 2-s2.0-28044463563 10.1073/pnas.0508666102 (Pubitemid 41692690)
81. + T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. Journal of immunology 2008 181 11 7480 7488 2-s2.0-58149293662
82. Cantor H., Shinohara M. L., Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nature Reviews Immunology 2009 9 2 137 141 2-s2.0-58849083626 10.1038/nri2460
83. Yednock T. A., Cannon C., Fritz L. C., Sanchez-Madrid F., Steinmann L., Karin N., Prevention of experimental autoimmune encephalomyelitis by antibodies against α 4 β 1 integrin. Nature 1992 356 6364 63 66 2-s2.0-0026506799 10.1038/356063a0
84. Steinman L., Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nature Reviews Drug Discovery 2005 4 6 510 518 2-s2.0-20844454381 10.1038/nrd1752 (Pubitemid 40861993)
85. Shaw P. J., Lukens J. R., Burns S., Chi H., McGargill M. A., Kanneganti T. D., Cutting edge: critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis. Journal of Immunology 2010 184 9 4610 4614 2-s2.0-77954478334 10.4049/jimmunol.1000217